Our new AI assistant can help patients, caregivers, and researchers find important information faster. Click the logo in the lower right corner to try it.
For patients and families affected by fibrolamellar cancer (FLC), hope is built through progress. Every discovery, every research collaboration, and every clinical trial brings us closer to better treatments for this devastating disease. Today, that progress is becoming increasingly tangible. Researchers are translating laboratory discoveries into clinical trials that offer new treatment opportunities for people …
A clinical trial of a new combination immune therapy specifically designed for fibrolamellar carcinoma (FLC) is beginning at the Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University (Baltimore, MD). The study is led by Drs. Marina Baretti and Mark Yarchoan. Importantly, this trial builds directly on findings from earlier studies that demonstrated the promise …
Registration is now open for the Patient & Family Gathering to be held on September 18 – 20, 2026, at the Lake Mansfield Trout Club in Stowe, Vermont. This unique event brings together patients, families and caregivers dealing with fibrolamellar, helping them build connections and friendships with others facing similar challenges. Please click here to …
Participation in clinical trials can be critical for fibrolamellar carcinoma patients—but the cost of travel, lodging, and time away from work or school can prevent many from enrolling. FCF is working to reduce these barriers with its Clinical Trial Patient Assistance Program, which provides housing assistance for patients with financial need while they are participating …
A recent article from the University of Wisconsin highlights ongoing progress in fibrolamellar carcinoma (FLC) research led by Dr. Sean Ronnekleiv-Kelly, a surgical oncologist focused on improving outcomes for this ultra-rare liver cancer. Dr. Ronnekleiv-Kelly’s work centers on understanding how these tumors develop and identifying potential treatment targets. His lab studies patient tumors and pre-clinical …
In a recent study funded by FCF, researchers at the University of Washington, Fred Hutchinson Cancer Center, and Cornell University shed important light on why immunotherapy has struggled to work in fibrolamellar carcinoma (FLC). Led by Dr. Venu G. Pillarisetty and Dr. Praveen Sethupathy, a collaborative, multidisciplinary team set out to understand why treatments like …
A landmark, evidence‑based clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma (FLC) has been released online ahead of publication in the journal Hepatology. Developed by a panel of 20 expert physicians from 15 leading cancer centers and supported by the Fibrolamellar Cancer Foundation, the guideline affirms that FLC is a biologically distinct cancer …
We are excited to announce the publication of a landmark paper in Nature Medicine highlighting a major advance in targeted immunotherapy for fibrolamellar carcinoma (FLC). The article, A Therapeutic Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma: A Phase 1 Trial, describes a collaborative effort by researchers at the Johns Hopkins University School of Medicine (Baltimore, MD) …
Today, on World Cancer Research Day, we join the global cancer community in recognizing the power of research to transform lives. This year’s theme, “Cancer Research Needs Us All,” resonates with our mission at the Fibrolamellar Cancer Foundation (FCF)—where patients, families, researchers, and supporters unite to accelerate progress against fibrolamellar carcinoma (FLC), a rare and …